Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRENAL septic shock hydrocortisone trial
ACTRN12611001042932Phase 4Completed
- Sponsor
- The George Institute for Global Health
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 4, randomised, double-blind trial in septic shock comparing Hydrocortisone with Placebo (2 arms). Primary endpoint: All-cause mortality at 90 days. Started Jun 2012; status: completed.
02
Drugs
hydrocortisone
03
Conditions
septic shock
Beyond the preview
Go deeper on ACTRN12611001042932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001042932.